Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tamoxifen. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 8/20 | 1.00 |
| ▸ | ESR2 | Q92731 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | ESRRG | P62508 | 3/20 | 1.00 |
| ▸ | PGR | P06401 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | HTR6 | P50406 | 2/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | GBA1 | P04062 | 1/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 1/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tamoxifen SCHEMBL119181 | 1.00 | ESR1 (1.00) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL17262082 | 1.00 | ESR1 (1.00) | ESR1ESR2MAPTMEN1TP53 | |
| SCHEMBL29659348 | 1.00 | ESR1 (1.00) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL4084 | 1.00 | ESR1 (1.00) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL4085 | 1.00 | ESR1 (1.00) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL17262111 | 1.00 | ESR1 (1.00) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL5789295 | 0.99 | ESR1 (0.97) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL3794383 | 0.99 | ESR1 (0.97) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL4323848 | 0.99 | ESR1 (0.97) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL4323842 | 0.99 | ESR1 (0.97) | ESR1ESR2MAPTMEN1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 262 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12280059-B2 | Acyl-CoA synthetase 4 (ACSL4) inhibitory compound | CONSEJO NACIONAL DE INVESTIGACIONES CIENTÍFICAS Y TÉCNICAS (CONICET) (AR) | 2025-04-22 | — | — | US | claimed |
| EP-3927434-B1 | ACYL-COA SYNTHETASE 4 (ACSL4) INHIBITORY COMPOUND | CONSEJO NACIONAL DE INVESTIGACIONES CIENTIFICAS Y TECN CONICET (AR) | 2024-10-16 | — | — | EP | claimed |
| CN-113278598-B | Biological enzyme system for preparing drug metabolites and application thereof | 山东大学 | 2022-08-30 | — | — | CN | claimed |
| CN-114929708-A | 4- [ [ (7-aminopyrazolo [1,5-A ] pyrimidin-5-yl) amino ] methyl ] piperidin-3-ol compounds and their therapeutic use | 卡里克治疗有限公司 | 2022-08-19 | — | — | CN | claimed |
| US-20220133731-A1 | ACYL-COA SYNTHETASE 4 (ACSL4) INHIBITORY COMPOUND | CONSEJO NACIONAL DE INVESTIGACIONES CIENTÍFICAS Y TÉCNICAS (CONICET) (AR) | 2022-05-05 | — | — | US | claimed |
| EP-0710116-B1 | PREVENTION AND TREATMENT OF PATHOLOGIES ASSOCIATED WITH ABNORMALLY PROLIFERATIVE SMOOTH MUSCLE CELLS | PONIARD PHARMACEUTICALS INC (US) | 2008-09-03 | — | — | EP | claimed |
| EP-1510220-B1 | Therapeutic inhibitor of vascular smooth muscle cells | PONIARD PHARMACEUTICALS INC (US) | 2008-07-23 | — | — | EP | claimed |
| US-7393864-B2 | Use of ClC3 chloride channel blockers to modulate vascular tone | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2008-07-01 | — | — | US | claimed |
| US-7220782-B1 | Methods to reduce the sensitivity of endothelially-compromised vascular smooth muscle | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2007-05-22 | — | — | US | claimed |
| US-20060100168-A1 | Method of treating cancer using adenosine and its analogs | THE TRUSTEE OF BOSTON UNIVERSITY (US) | 2006-05-11 | — | — | US | claimed |
| EP-0702557-A1 | THERAPEUTIC INHIBITOR OF VASCULAR SMOOTH MUSCLE CELLS | NEORX CORPORATION (US) | 1996-03-27 | — | — | EP | claimed |
| US-5472985-A | Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells | NEORX CORPORATION (US) | 1995-12-05 | — | — | US | claimed |
| WO-1994026291-A1 | THERAPEUTIC INHIBITOR OF VASCULAR SMOOTH MUSCLE CELLS | NEORX CORPORATION (US) | 1994-11-24 | — | — | WO | claimed |
| WO-1994026303-A1 | PREVENTION AND TREATMENT OF PATHOLOGIES ASSOCIATED WITH ABNORMALLY PROLIFERATIVE SMOOTH MUSCLE CELLS | NEORX CORPORATION (US) | 1994-11-24 | — | — | WO | claimed |
| EP-0153160-B1 | NOVEL CYTOTOXIC AMINOALKYL PHENOL ETHERS | The University of Manitoba (CA) | 1989-05-10 | — | — | EP | claimed |
| US-4803227-A | N,N-DIALKYL-2-//4-PHENYLMETHYL/PHENOXY/ETHANAMINE AND TAMOXIFE N | THE UNIVERSITY OF MANITOBA (CA) | 1989-02-07 | — | — | US | claimed |
| EP-0127128-B1 | PROCESS FOR THE CONVERSION OF THE E ISOMER OF 1,2-DIPHENYL-1-(4-(2-DIMETHYLAMINOETHOXY)-PHENYL)-1-BUTENE TO TAMOXIFEN HCL | Bristol-Myers Company (US) | 1987-02-25 | — | — | EP | claimed |
| EP-0153160-A1 | Novel cytotoxic aminoalkyl phenol ethers | The University of Manitoba (CA) | 1985-08-28 | — | — | EP | claimed |
| US-4536516-A | Alkene derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-08-20 | — | — | US | claimed |
| EP-0127128-A1 | Process for the conversion of the E isomer of 1,2-diphenyl-1-(4-(2-dimethylaminoethoxy)-phenyl)-1-butene to tamoxifen HCl | Bristol-Myers Company (US) | 1984-12-05 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12280059-B2 | Acyl-CoA synthetase 4 (ACSL4) inhibitory compound | ACSL4, ACSL3, ACSL1 | ESR1 548/4885ESR2 813/4885MAPT 3159/4885 |
| US-20220133731-A1 | ACYL-COA SYNTHETASE 4 (ACSL4) INHIBITORY COMPOUND | ACSL4, ACSL3, ACSL1 | ESR1 548/4885ESR2 813/4885MAPT 3159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.